PATHOGENIC PARTICULARITIES OF CARDIOVASCULAR CONTINUUM IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE
https://doi.org/10.18093/0869-0189-2016-26-5-610-617
Abstract
Chronic obstructive pulmonary disease (COPD) is currently considered as a systemic disease with multiple extrapulmonary manifestations which can negatively affect the prognosis. Cardiovascular abnormalities are main systemic manifestations of COPD. Cardiovascular diseases and COPD have common pathogenic features that include the systemic inflammatory response, oxidative stress and endothelial dysfunction. Main pathogenic mechanisms of this comorbidity were discussed in this review.
About the Authors
N. T. Vatutin
M.Gor'kiy Donetsk National Medical University: 14; Il'icha av., Donetsk, 83005, Ukraine;
V.K.Gusak State Institute of Urgent and Reconstructive Surgery, National Medical Science Academy of Ukraine: 47, Leninskiy av., Donetsk, 83000, Ukraine
Ukraine
MD, Professor, Head of Department of Hospital Internal Medicine
Ukraine
MD, Professor, Head of Department of Hospital Internal Medicine
A. S. Smirnova
M.Gor'kiy Donetsk National Medical University: 14; Il'icha av., Donetsk, 83005, Ukraine;
Ukraine
PhD, Assistant Lecturer at Department of Hospital Internal Medicine
Ukraine
PhD, Assistant Lecturer at Department of Hospital Internal Medicine
D. V. Bort
M.Gor'kiy Donetsk National Medical University: 14; Il'icha av., Donetsk, 83005, Ukraine;
Ukraine
Junior Physician at V.K.Gusak’ State Institute of Urgent and Reconstructive Surgery
Ukraine
Junior Physician at V.K.Gusak’ State Institute of Urgent and Reconstructive Surgery
G. G. Taradin
M.Gor'kiy Donetsk National Medical University: 14; Il'icha av., Donetsk, 83005, Ukraine;
Ukraine
PhD, Associate Professor at Department of Hospital Internal Medicine
Ukraine
PhD, Associate Professor at Department of Hospital Internal Medicine
References
1. Murray C.J., Lopez A.D. Measuring the global burden of disease. N. Engl. J. Med. 2013; 369: 448–457.
2. Agusti A., Calverley P.M., Celli B. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.
3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (Global Initiative for Chronic Obstructive lung Disease (GOLD). The updated 2015 report is available at www.goldcopd.com).
4. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. Federal clinical guidelines on diagnosis and management of chronic obstructive pulmonary disease. Pul'monologiya. 2014; 3: 15–54 (in Russian).
5. Pan J., Xu L., Cai S.X. et al. The association of pulmonary function with carotid atherosclerosis in older Chinese: Guangzhou Biobank Cohort Study-CVD Subcohort. Atherosclerosis. 2015; 243 (2): 469–476.
6. Kryukov N.N., Shanina I.Yu., Protasov A.D. Results of functional tests in patients with comorbidity of coronary heart disease and chronic obstructive pulmonary disease. Fundamental'nye issledovaniya. 2011; 2: 83–88 (in Russian).
7. Sin D.D., Man S.F.P. Chronic obstructive pulmonary disease as a risk factor for cardiovascular morbidity and mortality. Proc. Am. Thorac. Soc. 2005; 2: 8–11.
8. Belovol A.N., Knyaz'kova I.I., Tsygankov A.I. et al. Improvement in therapy of patients with chronic heart failure and chronic obstructive pulmonary disease. Praktichna angіologіya. 2015; 3 (70): 57–62 (in Russian).
9. Kubazhi Khalil. Disease course and prognosis in patients with comorbidity of chronic obstructive pulmonary disease, coronary heart disease and hypertension: Diss. Ryazan'; 2013 (in Russian).
10. Rodriguez-Miguelez P., Seigler N., Bass L. et al. Assessments of endothelial function and arterial stiffness are reproducible in patients with COPD. Int. J. Chron. Obstruct. Pulm. Dis. 2015; 10: 1977–1986.
11. Campo G., Pavasini R., Malagù M. et al. Chronic obstructive pulmonary disease and ischemic heart disease comorbidity: overview of mechanisms and clinical management. Cardiovasc. Drugs Ther. 2015; 29 (2): 147–157.
12. Kutsenko M.A., Chuchalin A.G. A paradigm of comorbidity of chronic obstructive pulmonary disease and coronary heart disease. Russkiy meditsinskiy zhurnal. 2014; 5: 389–393 (in Russian).
13. Yarmysh N.V., Groznaya L.N. Endothelial dysfunction and regulatory factors. Vіsnik problem bіologії і meditsini. 2014; 2 (111): 37–43 (in Russian).
14. Fabbri L.M., Rabe K.F., Ukena C. et al. From COPD to chronic systemic inflammatory syndrome? Lancet. 2007; 370: 797–799.
15. Mamaeva M.G., Demko I.V., Verigo Ya.I. et al. Markers of systemic inflammation and endothelial dysfunction in patients with chronic obstructive pulmonary disease. Sibirskoe meditsinskoe obozrenie. 2014; 1 (85): 12–19 (in Russian).
16. Pepene C.E. Soluble platelet/endothelial cell adhesion molecule (sPECAM)-1 is increased in polycystic ovary syndrome and related to endothelial dysfunction. Gynecol. Endocrinol. 2012; 28 (5): 370–374.
17. Hou H.F., Yuan N., Guo Q. et al. Citreoviridin enhances atherogenesis in hypercholesterolemic ApoE-deficient mice via upregulating inflammation and endothelial dysfunction. PLoS One. 2015; 10 (5): e0125956.
18. Bakakos P., Patentalakis G., Papi A. Vascular biomarkers in asthma and COPD. Curr. Top. Med. Chem. 2016; 16 (14): 1599–1609.
19. Poplavskaya E.E., Lis M.A. Endothelial function and phagocytosis activity in comorbidity of chronic obstructive pulmonary disease and coronary heart disease. Zhurnal Grodnenskogo gosudarstvennogo meditsinskogo universiteta. 2010; 1 (29): 29–31 (in Russian).
20. Zarubina E.G., Mishina E.A., Osadchuk M.A. A role of endothelial dysfunction in pathogenesis of heart and respiratory disease comorbidity. Klinicheskaya meditsina. 2006; 5: 31–34 (in Russian).
21. Takahashi T., Kubo H. The role of microparticles in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulm. Dis. 2014; 9: 303–314.
22. Tanaseanu C., Tudor S., Tamsulea I. et al. Vascular endothelial growth factor, lipoporotein-associated phospholipase A2, sP-selectin and antiphospholipid antibodies, biological markers with prognostic value in pulmonary hypertension associated with chronic obstructive pulmonary disease and systemic lupus erithematosus. Eur. J. Med. Res. 2007; 12 (4): 145–151.
23. Boeck L., Mandal J., Costa L. et al. Longitudinal measurement of serum vascular endothelial growth factor in patients with chronic obstructive pulmonary disease. Respiration. 2015; 90 (2): 97–104.
24. Feng E.Z., Yang S.Y., Huang N.X. et al. Plasma endothelin-1 and nitric oxide correlate with ligustrazine alleviation of pulmonary artery hypertension in patients of chronic cor pulmonale from high altitude plateau during acute exacerbation. Zhongguo Ying Yong Sheng Li Xue Za Zhi. 2014; 30 (6): 532–537.
25. Akhmineeva A.Kh. Biochemical markers of endothelial dysfunction in chronic obstructive pulmonary disease concurrent with hypertensive disease or coronary heart disease. [Article in Russian]. Ter. Arkh. 2014; 86 (3): 20–23.
26. Pribylov S.A. Pulmonary hypertension, endothelial dysfunction and their correction with Lisinopril in patients with heart failure due to coronary heart disease and chronic obstructive pulmonary disease comorbidity. Kardiologiya. 2006; 46 (9): 36–40 (in Russian).
27. Janssen W.J., Yunt Z.X., Muldrow A. et al. Circulating hematopoietic progenitor cells are decreased in COPD. COPD. 2014; 11 (3): 277–289.
28. Pizarro S., García-Lucio J., Peinado V.I. et al. Circulating progenitor cells and vascular dysfunction in chronic obstructive pulmonary disease. PLoS One. 2014; 9 (8): e106163.
29. Liu P., Zhang H., Liu J. et al. Changes of number and function of late endothelial progenitor cells in peripheral blood of COPD patients combined with pulmonary hypertension. Thorac. Cardiovasc. Surg. 2014 Sep 16. Epub ahead of print.
30. Paschalaki K.E., Starke R.D., Hu Y. et al. Dysfunction of endothelial progenitor cells from smokers and chronic obstructive pulmonary disease patients due to increased DNA damage and senescence. Stem. Cells. 2013; 31 (12): 2813–2826.
31. Yoshii A., Iizuka K., Dobashi K. et al. Relaxation of contracted rabbit tracheal and human bronchial smooth muscle by Y-27632 through inhibition of Ca2+ sensitization. Am. J. Respir. Cell Mol. Biol. 1999; 20 (6): 1190–1200.
32. Fukumoto Y., Matoba T., Ito A. et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart. 2005; 91 (3): 391–392.
33. Steioff K., Rütten H., Busch A.E. et al. Long term Rho-kinase inhibition ameliorates endothelial dysfunction in LDL-Receptor deficient mice. Eur. J. Pharmacol. 2005; 512 (2–3): 247–249.
34. Bei Y., Duong-Quy S., Hua-Huy T. et al. Activation of RhoA/Rho-kinase pathway accounts for pulmonary endothelial dysfunction in patients withchronic obstructive pulmonary disease. Physiol. Rep. 2013; 1 (5): e00105.
35. Song D., Fang G., Greenberg H., Liu S.F. Chronic intermittent hypoxia exposure-induced atherosclerosis: a brief review. Immunol. Res. 2015; 63 (1–3): 121–130.
36. Provotorov V.M., Budnevskiĭ A.V., Semenkova G.G., Shishkina E.S. Proinflammatory cytokines in combination of coronary heart disease and chronic obstructive pulmonary disease. Klin. Med. (Mosk.). 2015; 93 (2): 5–9.
37. Karpova A.A., Reyder T.N. Coronary injury in patients with multi-focal atherosclerosis and chronic obstructive pulmonary disease. Fundamental'nye issledovaniya. 2014; 4: 286–290 (in Russian).
38. Lin G.M., Liu K., Colangelo L.A. et al. Low-density lipoprotein cholesterol concentrations and sssociation of high-sensitivity C-reactive protein concentrations with incident coronary heart disease in the multi-ethnic study of atherosclerosis. Am. J. Epidemiol. 2016;183 (1): 46–52.
39. Stamler J., Neaton J.D., Cohen J.D. et al. Multiple risk factor intervention trial revisited: a new perspective based on nonfatal and fatal composite endpoints, coronary and cardiovascular, during the trial. J. Am. Heart Assoc. 2012; 1 (5): e003640.
40. Nilsson M., Trehn G., Asplund K. Use of complementary and alternative medicine remedies in Sweden. A population-based longitudinal study within the northern Sweden MONICA Project. Multinational Monitoring of Trends and Determinants of Cardiovascular Disease. J. Intern. Med. 2001; 250 (3): 225–233.
41. Dursunoglu N., Dursunoglu D., Yıldız A.İ. et al. Severity of coronary atherosclerosis in patients with COPD. Clin. Respir. J. 2015. doi: 10.1111/crj.12412. [Epub ahead of print].
42. Vertkin A.L., Skotnikov A.S., Gubzhokova O.M. Comorbidity in patients with chronic obstructive pulmonary disease: a role of systemic inflammation and clinical and pharmacological role of roflumilast. Lechashchiy vrach. 2013; 11: 85–88 (in Russian).
43. Akramova E.G., Struchkov P.V. Severity of carotid atherosclerosis in patients with chronic obstructive pulmonary disease. Pul'monologiya. 2013; 3: 45–48 (in Russian).
44. Provotorov V.M., Budnevskiy A.V., Semenkova G.G., Shishkina E.S. Proinflammatory cytokines in comorbidity of coronary heart disease and chronic obstructive pulmonary disease. Klinicheskaya meditsina. 2015; 93 (2): 5–9 (in Russian).
45. Polunina O.S., Mikhaylova I.A, Kudryasheva I.A. Hemostasis in elderly patients with chronic obstructive pulmonary disease. Fundamental'nye issledovaniya. 2005; 2: 32–33 (in Russian).
46. Kinyaykin M.F., Sukhanova G.I., Udovichenko I.A., et al. A role of hypoxemia in development of myocardial injury and hemostasis abnormalities in patients with chronic obstructive pulmonary disease. Byulleten' fiziologii i patologii dykhaniya. 2011; 41: 8–12 (in Russian).
47. Biljak V.R., Pancirov D., Cepelak I. et al. Platelet count, mean platelet volume and smoking status in stable chronic obstructive pulmonary disease. Platelets. 2011; 22 (6): 466–470.
48. Kostin V.I., Prostakishina Yu.M., Shangina O.A., Solodilova T.P. Blood aggregation in elderly patients with COPD and depressive disorders. Klinicheskaya gerontologiya. 2012; 11: 21–24 (in Russian).
49. Martin-Rodriguez E., Guillen-Grima F., Martí A, Brugos-Larumbe A. Comorbidity associated with obesity in a large population: The APNA study. Obes. Res. Clin. Pract. 2015; 9 (5): 435–447.
50. Liu Y., Pleasants R.A., Croft J.B., Lugogo N. et al. Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease. Respir. Med. 2015; 109 (7): 851–859.
51. Laurikka A., Vuolteenaho K., Toikkanen V., Rinne T. Adipocytokine resistin correlates with oxidative stress and myocardial injury in patients undergoing cardiac surgery. Eur. J. Cardiothorac. Surg. 2014; 46 (4): 729–736.
52. Lis I., Pilarski Ł., Bogdański P. Omentin – a newly-discovered adipocytokine in insulin resistance pathogenesis. Pol. Merkur. Lekarski. 2015; 39 (229): 56–60.
53. Nikseresht M., Sadeghifard N., Agha-Alinejad H., Ebrahim K. Inflammatory markers and adipocytokine responses to exercise training and detraining in men who are obese. J. Strength. Cond. Res. 2014; 28 (12): 3399–3410.
Review
For citations:
Vatutin N.T., Smirnova A.S., Bort D.V., Taradin G.G. PATHOGENIC PARTICULARITIES OF CARDIOVASCULAR CONTINUUM IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE. PULMONOLOGIYA. 2016;26(5):610-617. (In Russ.) https://doi.org/10.18093/0869-0189-2016-26-5-610-617
Views:
1084
Email this article 